The estimated Net Worth of Jeffrey D Capello is at least $8.11 Milion dollars as of 13 June 2024. Jeffrey Capello owns over 1,976 units of Revvity stock worth over $227,813 and over the last 21 years Jeffrey sold PKI stock worth over $7,883,514.
Sign up
Jeffrey Capello PKI stock SEC Form 4 insiders trading
Jeffrey has made over 30 trades of the Revvity stock since 2004, according to the Form 4 filled with the SEC. Most recently Jeffrey exercised 1,976 units of PKI stock worth $227,813 on 13 June 2024.
The largest trade Jeffrey's ever made was selling 525,000 units of Revvity stock on 29 August 2013 worth over $5,607,000. On average, Jeffrey trades about 25,834 units every 128 days since 2003. As of 13 June 2024 Jeffrey still owns at least 1,976 units of Revvity stock.
You can see the complete history of Jeffrey Capello stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jeffrey Capello's mailing address?
Jeffrey's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Revvity
Over the last 26 years, insiders at Revvity have traded over $204,298,889 worth of Revvity stock and bought 55,200 units worth $1,110,570 . The most active insiders traders include Alexis P Michas, Gregory L Summe a Robert F Friel. On average, Revvity executives and independent directors trade stock every 25 days with the average trade being worth of $6,184,617. The most recent stock trade was executed by Andrew Okun on 13 April 2023, trading 2,435 units of PKI stock currently worth $332,402.
What does Revvity do?
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.
What does Revvity's logo look like?
Complete history of Jeffrey Capello stock trades at Agios Pharmaceuticals Inc, Biogen Inc, Neogen, Boston Scientific a Revvity
Revvity executives and stock owners
Revvity executives and other stock owners filed with the SEC include:
-
Dr. Prahlad R. Singh Ph.D.,
CEO, Pres & Director -
Prahlad Singh,
President, Chief Executive Officer, Director -
Joel Goldberg,
Senior Vice President - Administration, General Counsel, Secretary -
James M. Mock,
Sr. VP & CFO -
Joel S. Goldberg,
Sr. VP of Admin., Gen. Counsel & Sec. -
James Mock,
Chief Financial Officer, Senior Vice President -
Deborah Butters,
Chief Human Resource Officer, Senior Vice President -
Tajinder Vohra,
Sr. VP of Global Operations -
Alexandros Michas,
Independent Non-Executive Chairman of the Board -
Samuel Chapin,
Independent Director -
Peter Barrett,
Independent Director -
Pascale Witz,
Independent Director -
Frank Witney,
Independent Director -
Sylvie Gregoire,
Independent Director -
Michel Vounatsos,
Independent Director -
Andrew Okun,
Chief Accounting Officer, Vice President -
Tajinder Vohra,
Senior Vice President, Global Operations -
Daniel Tereau,
Senior Vice President, Strategy and Business Development -
Masoud Toloue,
Sr. VP of Diagnostics -
Miriame Victor,
Sr. VP & Chief Commercial Officer -
Robert Francis Friel,
Advisor -
Stephen Barr Willoughby,
VP of Investor Relations -
Andrew Okun,
VP, Chief Accounting Officer & Treasurer -
Michelle Mc Murry Heath,
Director -
Nicholas A Lopardo,
Director -
James Corbett,
See Remarks -
Alexis P Michas,
Director -
Vicki L Sato,
Director -
Kenton J Sicchitano,
Director -
Robert F Friel,
Chief Financial Officer -
Patrick J Sullivan,
Director -
Frank Anders Wilson,
SVP, CFO & CAO -
John A Roush,
Vice President -
Michael Louis Battles,
VP & Chief Accounting Officer -
Jeffrey D Capello,
Chief Accounting Officer -
Gregory L Summe,
Chairman & CEO -
Katherine A O Hara,
SVP & General Counsel -
Richard F Walsh,
Senior Vice President -
Tamara J Erickson,
Director -
Robert A Barrett,
Sr. Vice President -
Terrance L Carlson,
Sr. VP & General Counsel -
Peter B Coggins,
Sr. Vice President -
John Patrick Murphy,
Sr. Vice President -
John R Letcher,
Senior Vice President, HR -
Jonathan P. Di Vincenzo,
See Remarks -
James C Mullen,
Director -
Maurice H. Tenney,
See Remarks -
Daniel R Marshak,
SVP & CSO -
E Kevin Hrusovsky,
See Remarks -
G Robert Tod,
Director -
Gabriel Schmergel,
Director -
Miriame Victor,
Please See Remarks -
Maxwell Krakowiak,
Please See Remarks